Recursion Pharmaceuticals, Inc.
RXRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRecursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation,. Valued at $1.56B, RXRX is a small-cap name in its sector. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Market Cap
$1.56B
Beta
0.99
P/E (TTM)
—
P/E (Fwd)
-3.13
EPS (TTM)
$-1.16
EPS (Fwd)
$-0.94
ROE
-57.2%
ROA
-27.7%
Cash
$654.5M
Total Debt
$72.4M
Free CF
-$177.8M
52W Change
-49.6%
Annual Financials
Cash vs Debt
With $654.5M in cash and $72.4M in debt, RXRX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$177.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -57.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $39.7M (2022) to $74.3M (2025), reflecting a 87% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Recursion Pharmaceuticals, Inc. and its sector.